Association of IGFBP-6 Expression with Metabolic Syndrome and Adiponectin and IGF-IR Receptor Levels in Colorectal Cancer

  • Yunusova, Natalia V (Tomsk Cancer Research Institute) ;
  • Spirina, Liudmila V (Tomsk Cancer Research Institute) ;
  • Frolova, Alena E (Tomsk Cancer Research Institute) ;
  • Afanas'ev, Sergey G (Tomsk Cancer Research Institute) ;
  • Kolegova, Elena S (Tomsk Cancer Research Institute) ;
  • Kondakova, Irina V (Tomsk Cancer Research Institute)
  • Published : 2016.08.01


Purpose:To assess IGFBP-6 expression in relation with the presence of the metabolic syndrome, adiponectin receptors (AdipoR1 and AdipoR2) and IGF-IR levels in colorectal adenocarcinoma cases. Materials and Methods: IGFBP-6 mRNA and protein levels were analyzed using real-time quantitative PCR and Western blotting in 46 patients. ELISA and flow cytometry were used for evaluation of AdipoR1, AdipoR2 and IGF-IR. Results: The results showed that IGFBP-6 mRNA expression and the IGFBP-6 content were higher in tumor tissue samples of colorectal cancer patients with tahtn without metabolic syndrome. In addition, the IGFBP-6 mRNA expression was associated with tumor invasion (tumor size) and the IGFBP-6 protein level was associated with nodal status. Positive correlations and positive nonlinear relations were found between the IGFBP-6 level and the AdipoR1 and AdipoR2 contents in colorectal cancer patients. Conclusions: The IGFBP-6 mRNA level and protein level were found to be associated with presence of metabolic syndrome. Positive correlations indicated probable cross-talk between the IGF-IR-mediated and adiponectin-mediated signaling pathways in colorectal carcinomas. IGFBP-6 may be considered as a potential biomarker associated with lymphogenous metastasis and the metabolic syndrome in colorectal cancer.


Colorectal cancer;insulin-like growth factor binding protein;metabolic syndrome;AdipoR;IGF-IR


Supported by : Russian Foundation for Basic Research


  1. Ahmad W, Shabbiri K, Ijaz B, et al (2011). Serine 204 phosphorylation and O-${\beta}$-GlcNAC interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma. Virol J, 8, 208.
  2. Ayyildiz T, Dolar E, Ugras N, et al (2014). Association of adiponectin receptor (Adipo-R1/-R2) expression and colorectal cancer. Asian Pac J Cancer Prev, 15, 9385-90.
  3. Bach LA, Fu P, Yang Z (2013). Insulin-like growth factor-binding protein-6 and cancer. Clin Sci (Lond), 124, 215-29.
  4. Bach LA (2015). Recent insight into the action of IGFBP-6. J Cell Commun Signal, 9, 189-200.
  5. Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54.
  6. Ivanova EV, Kondakova IV, Spirina LV, et al (2014). Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. Bulletin Experimental Biol Med, 157, 781-4.
  7. Kim EJ, Schaffer BS, Kang YH, et al (2002). Decreased production of insulin-like growth factor-binding protein (IGFBP)-6 by transfection of colon cancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of cell proliferation. J Gastroenterol Hepatol, 17, 563-70.
  8. Leng SL, Leeding KS, Whitehead RH, et al (2001). Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-IIinduced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol, 174, 121-7.
  9. Marinaro JA, Neumann GM, Russo VC, et al (2000). O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur J Biochem, 267, 5378-86.
  10. Mauro L, Pellegrino M, De Amicis F, et al (2014). Evidence that estrogen receptor ${\alpha}$ interferes with adiponectin effects on breast cancer cell growth. Cell Cycle, 13, 553-64.
  11. Mauro L, Naimo GD, Riccio E, et al (2015). Cross-talk between adiponectin and IGF-RI in breast cancer. Frontiers Oncol, 5, 1-8.
  12. Minniti CP, Luan D, O'Grady C, et al (1995). Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ, 6, 263-9.
  13. Ogunwobi O, Beales IL (2007). The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3kinase/Akt. Int J Colorectal Dis, 22, 401-9.
  14. Pennisi PA, Barr V, Nunez NP, et al (2002). Reduced expression of insuline-like growth factor I receptors in MCF breast cancer cells leads to a more metastatic phenotype. Cancer Res, 62, 6529-37.
  15. Resch A, Langer C (2013). Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol, 19, 8515-26.
  16. Samani AA, Yakar S, LeRoith D, et al (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insight. Endocrine Reviews, 28, 20-47.
  17. Spirina LV, Bochkareva NV, Kondakova IV, et al (2012). Regulation of insulin-like growth NF-${\kappa}B$ proteasome system in endometrial cancer. Molecular Biol, 46, 407-13.
  18. Spirina LV, Yunusova NV, Kondakova IV, et al (2012). Association of growth factors, HIF-1 and NF-${\kappa}B$ expression with proteasome in endometrial cancer. Mol Biol Rep, 39, 8655-62.
  19. Sugiyama M, Takahashi H, Hosono K, et al (2009). Adiponectin inhibits colorectal cancer cell growth through the AMPK/ mTOR pathway. Int J Oncol, 34(2), 339-44.
  20. Tae CH, Kim SE, Jung SA, et al (2014). Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC Cancer, 14, 811.
  21. Yunusova NV, Spirina LV, Kondakova IV, et al (2013). The relationship of metalloproteinase PAPP-A expression with the expression of growth and transcriptional factors in endometrial cancer. Biology Bulletin, 40, 253-59.
  22. Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). The insulin-like growth factors system in ovarian cancer metastasis: the relation with p45 Ser ${\beta}$-catenin. Molekulyrnaya Meditsina, 4, 17-22. [in Russian].
  23. Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). Serum adipokines and their receptors in endometrial and colon cancer patients: relationship with tumor invasion and metastasis. Vopr Onkol, 61, 619-23.
  24. Zhou JR, Blac${\kappa}B$urn GL, Walker WA (2007). Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr, 86, 817-9.